Literature DB >> 24508409

Optimization of precursor synthesis, formulation and stability of 1'-[18F]fluoroethyl-β-D-lactose ([18F]FEL) for preclinical studies in detection of pancreatic cancer.

Vincenzo Paolillo1, Louis De Palatis1, Mian M Alauddin2.   

Abstract

INTRODUCTION: 1'-[(18)F]Fluoroethyl-β-D-lactose ([(18)F]FEL) is a new PET imaging agent for early detection of pancreatic cancer and hepatocellular carcinoma. We previously reported the syntheses of [(18)F]FEL using a bromo- and a tosyl- precursor, followed by an improved method using a nosyl-precursor. However, some steps in the synthesis of the precursor appeared to be problematic producing low yields. Here, we report on an optimized method for synthesis of the precursor and production of [(18)F]FEL; we also describe [(18)F]FEL's formulation and stability.
METHODS: Acetylation of D-lactose 1 was performed following a literature procedure to obtain 1',2',3',6',2,3,4,6-D-lactose octa-acetate 2a/2b. Bromination of 2a/2b was performed using HBr/acetic acid to produce 1'-bromo-2',3',6',2,3,4,6-hepta-O-acetyl-α-D-lactose 3. Coupling of 3 with ethylene glycol was performed in the presence of Ag-tosylate and an excess of ethylene glycol to produce 4a. Compound 4a was reacted with p-nitrophenylsulfonyl chloride to produce the nosyl derivative 5. Radiofluorination of 5 was performed using K[(18)F]fluoride/kryptofix to obtain 6, which was purified by HPLC and hydrolyzed with Na-methoxide to produce 7.
RESULTS: Compound 2 (2a/2b) was obtained in 83% yield as a mixture of two anomeric products. Compound 3 was obtained from the 2a/2b mixture in 80% yield as one product. Coupling of 3 with ethylene glycol produced 4a in 90% yield. Compound 5 was obtained in 64% yield, and radiofluorination of 5 produced 6 in 62.5% ± 7.5% yields (n=8). Hydrolysis of 6 with Na-methoxide produced 7 in 42.0% ± 7.0% yield (n=8) from the end of bombardment.
CONCLUSIONS: A simple 4-step synthesis of the precursor, compound 5, has been achieved with improved yields. A new formulation of [(18)F]FEL has been developed that allows the product to remain stable at ambient temperature for use in animal studies. This improved synthesis of the precursor and stable formulation of [(18)F]FEL should be useful for routine production of the radiotracer and its preclinical and, possibly, clinical applications.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fluorine-18; Lactose; PET; Pancreatic cancer

Mesh:

Substances:

Year:  2014        PMID: 24508409      PMCID: PMC3962678          DOI: 10.1016/j.nucmedbio.2014.01.002

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  21 in total

1.  Stability evaluation of (18)F-FDG at high radioactive concentrations.

Authors:  Leah R Walters; Katherine J Martin; Mark S Jacobson; Joseph C Hung; Elton A Mosman
Journal:  J Nucl Med Technol       Date:  2012-02-07

2.  Synthesis and ex vivo autoradiographic evaluation of ethyl-β-D-galactopyranosyl-(1,4')-2'-deoxy-2'-[18F]fluoro-β-D-glucopyranoside--a novel radioligand for lactose-binding protein: implications for early detection of pancreatic carcinomas with PET.

Authors:  Yunming Ying; Pradip Ghosh; Liwei Guo; Ashutosh Pal; Uday Mukhapadhyay; Zhenghong Peng; Hsin Hsien Yeh; Susanna Bertolini; Leo Garcia Flores; Daniel Young; Andrei Volgin; Suren Soghomonyan; William Bornmann; Craig Logsdon; Mian M Alauddin; Juri G Gelovani
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

Review 3.  C-type lectin-like domains.

Authors:  K Drickamer
Journal:  Curr Opin Struct Biol       Date:  1999-10       Impact factor: 6.809

4.  Improved detection and measurement of low levels of [18F]fluoride metabolized from [18F]-labeled pyrimidine nucleoside analogues in biological samples.

Authors:  Vincenzo Paolillo; Hsin Hsien Yeh; Uday Mukhopadhyay; Juri G Gelovani; Mian M Alauddin
Journal:  Nucl Med Biol       Date:  2011-07-08       Impact factor: 2.408

5.  Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations.

Authors:  C Cavard; B Terris; G Grimber; L Christa; V Audard; B Radenen-Bussiere; M-T Simon; C-A Renard; M-A Buendia; C Perret
Journal:  Oncogene       Date:  2006-01-26       Impact factor: 9.867

6.  Radiolysis of 2-[¹⁸F]fluoro-2-deoxy-D-glucose ([¹⁸F]FDG) and the role of ethanol, radioactive concentration and temperature of storage.

Authors:  Narayanna M Dantas; João E Nascimento; Nereide S Santos-Magalhães; Mércia L Oliveira
Journal:  Appl Radiat Isot       Date:  2012-10-30       Impact factor: 1.513

7.  Preparation of aminoethyl glycosides for glycoconjugation.

Authors:  Robert Sardzík; Gavin T Noble; Martin J Weissenborn; Andrew Martin; Simon J Webb; Sabine L Flitsch
Journal:  Beilstein J Org Chem       Date:  2010-07-29       Impact factor: 2.883

8.  The human HIP gene, overexpressed in primary liver cancer encodes for a C-type carbohydrate binding protein with lactose binding activity.

Authors:  L Christa; M Felin; O Morali; M T Simon; C Lasserre; C Brechot; A P Sève
Journal:  FEBS Lett       Date:  1994-01-03       Impact factor: 4.124

9.  Expression of HIP/PAP mRNA in human hepatoma cell lines.

Authors:  M Cervello; L Giannitrapani; M La Rosa; M Notarbartolo; N D'Alessandro; L Virruso; J L Iovanna; G Montalto
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

10.  A novel gene (HIP) activated in human primary liver cancer.

Authors:  C Lasserre; L Christa; M T Simon; P Vernier; C Bréchot
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

View more
  2 in total

1.  Preliminary evaluation of 1'-[(18)F]fluoroethyl-β-D-lactose ([(18)F]FEL) for detection of pancreatic cancer in nude mouse orthotopic xenografts.

Authors:  Thiruvengadam Arumugam; Vincenzo Paolillo; Daniel Young; XiaoXia Wen; Craig D Logsdon; Louis De Palatis; Mian M Alauddin
Journal:  Nucl Med Biol       Date:  2014-08-08       Impact factor: 2.408

2.  Preclinical PET imaging of HIP/PAP using 1'-18F-fluoroethyl-β-D-lactose.

Authors:  Shaobo Yao; Yaping Luo; Zhenzhong Zhang; Guilan Hu; Zhaohui Zhu; Fang Li
Journal:  Oncotarget       Date:  2017-09-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.